Member Info for B2HS2L

This is what it fells like waiting for NCYT management to come clean about 'everything' come Thursday:

https://pbs.twimg.com/media/FRL1UASXsAULO-z?format=jpg&name=large

3. DHSC dispute close to a favourable resolution
The next thing we hear about this will be in an RNS, - DA won't tweet that.
4. AIM shares thrive on sentiment - we can assume DA knows this, so lets see if he maximises the opportunity.

https://immunexpress.com/

"We have developed the fully automated SeptiCyte® RAPID cartridge, compatible with the Biocartis Idylla™ platform, enabling the quantification and analysis of gene expression from whole blood to diagnose sepsis in suspected patients. With this technology, we aim to improve clinical and economic outcomes for patients and to benefit all key healthcare stakeholders: medical professionals and payers."

Best we aim that question at DA, as GM is elsewhere.

I'd like to understand why we did not pursue the original agreement.
Immunexpress succeeded, so why are we not part of that success.
Sounds like a GM question for Thursday.

Sorry if I am too persistent on this, but further Abionic research reveals this from an undated press release:

https://abionic.com/en/news/worlds-fastest-sepsis-test-abionic-produces-result-five-minutes-when-tested-patients-london

World's Fastest Sepsis Test from Abionic Produces Result in Five Minutes when tested in Patients at London and Zurich Hospitals

"The UK National Institute for Health and Care Excellence (NICE) is urging hospital staff to treat people with life-threatning sepsis symptoms within one hour
University College London Hospitals (UCLH) evaluation highlighted that the 5 minutes abioSCOPE is perfectly adapted for use as a near-patient testing platform for accelerating time to results in hospitals
Sepsis in burn patients identified 24 hours before clinical symptoms in Zurich Hospital Intensive Care Units (ICU)
CE marked abioSCOPE PSP test to help assess the risk of sepsis in Emergency Rooms (ER) and ICU available for sales in Europe by the end of 2018"

Update on Abionic's research on Sepsis detection.

++++
29.04.21
https://actu.epfl.ch/news/startup-champion-seed-night-10-years-of-discoverin/

"Our sepsis test, which gives results in a few minutes as opposed to several hours at present, is doing very well in about ten countries and helps save lives every day. Unfortunately, it’s still not widely available in Switzerland, where the medical community is extremely wary. We’re also developing a Covid test as well as other diagnostic solutions such as allergy tests. We’re currently hoping to set up a major funding round to achieve this, because we’re up against multinational pharmaceutical companies that spend hundreds of millions in a single year on new tests. But we have a solid team, well-equipped facilities and fantastic technology: we are poised for rapid growth and demonstrate immense medico-commercial success."

+++
https://abionic.com/en/about-us
"OUR TEAM
In less than 10 years, we have demonstrated our ability to bring the company to a stage of full expansion. Currently, our team is composed of 50+ highly skilled employees.

Our dynamic team is highly effective, and we are committed to changing the world of in vitro diagnostics (IVD) by bringing rapid diagnostic solutions close to the patient."

+++
Abionic appears to have a first mover advantage in Sepsis detection, but doesn't explain why the medical community is 'extremely wary', - 50 jobs shows at least some successes.

Googling - Abionic Sepsis test "DHSC", or Abionic Sepsis test "UKHSA" retrieves nothing.

Hey Larry,

I also have a message from Mandy - passing questions I posted to DA, - maybe he's been reviewing questions all day.

So for 28th April

Just a reminder that the Strategy and Full Year 2021 Trading Update RNS - 25.01.2022,
under the heading 'Initial findings and conclusions from strategic review', is the book mark I expect him to build his strategy on.

Not sure why James McCarthy is invited, but perhaps he will tell us what the strategy is gonna cost, and that's what we're spending plenty of cash on.

Somehow I'm guessing the Investor Presentation is to introduce the shareholders to something completely novel.
Not sure why that is though.

22.01.2020 Portable device helps doctors diagnose sepsis faster
https://actu.epfl.ch/news/portable-device-helps-doctors-diagnose-sepsis-fast/
News of others research on Sepsis detection.

Haven't seen any update on this since.

Morning EXMEX, - Good job finding this opportunity.

Deputy Director – HCAI, Fungal, AMR, Stewardship & Sepsis
About the job
Summary
"The Deputy Director’s job is to build and lead the Healthcare Associated Infection, Fungal, Antimicrobial Resistance, Antimicrobial Usage & Sepsis Division (HCAI & AMRP). This involves providing scientific leadership on the detection and analysis of, and interventions concerning, infectious diseases in those areas, with the clear objective of significantly reducing their overall incidence. It is a critical role which supports the delivery of the primary UKHSA function to protect the public health.
Job description
Working with internal and external stakeholders, as Deputy Director – HCAI & AMRP Division will lead nationally on the prevention, control and reduction of infectious disease in their area. Specifically for AMR, the Deputy Director will ensure that the national action plan, for which UKHSA has responsibility, is fulfilled. They will also develop a strategic plan for multidisciplinary interventions over controlling AMR through close working with all relevant stakeholders. For HCAI, the director will develop a strategic plan for closely interacting with NHSEI on programmes to detect, monitor and develop interventions for reducing infection. They will work on developing strategy with the relevant HPRUs."
++++
* It seems DA had read the 'national action plan', for which UKHSA has responsibility.
It would not be surprising if R&D were working with UKHSA on finding ways to improve the plan, - thus meeting future needs as yet unmet.

* https://www.linkedin.com/feed/update/urn:li:activity:6869314872211996672/?lipi=urn%3Ali%3Apage%3Ad_flagship3_detail_base%3BKnIOWLJUSTyHhp5wUplarQ%3D%3D
This video highlights the global Infection, Fungal, and Antimicrobial Resistance needs.

* https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1070263/UK_AMR_5_year_national_action_plan.pdf
Pages 71 to 83 are of interest, especially pages 80-83.

https://www.express.co.uk/life-style/health/1599369/cancer-patient-therapy-genetic-clues

Cancer fight step closer to personalised therapy as genetic clues unearthed

British scientists are on the verge of revolutionising cancer treatment thanks to astonishing breakthroughs pinpointing genetic clues to the disease.
The "fantastic" pioneering techniques will allow personalised patient therapy and let doctors target killer cells with the best drugs.
Whole-genome sequencing of tumours from thousands of NHS patients has detected a “treasure trove” of previously unidentified patterns in cancer DNA.

+++

It would be great if NCYT could get a slice of the sequencing action.

It is not acceptable for a potentially large deal to have no basis in fact.
ie The company can say quite correctly that they have never mentioned, formally or informally that the deal exists.
How will they explain in the year end finances, the sale of many instruments?

Re my Wednesday 10:27 post

I have decided to send the following to David Allmond, as he prepares for the long promised 28.04 strategy review.

I feel shareholders deserve to see his presentation contain updates on these issues:

1 What information can be provided on the deal between IT-IS International instruments and TATA MD in India?
- No mention of this development is completely unacceptable to shareholders.

2 From Half Year 2021 results RNS - 27.09.2021 -
"Appointment of US General Manager and set-up of Novacyt US Inc"
- Please provide a progress update for this subject, last update 7 months ago.

3 CO-Prep - From 30.09.2021 RNS -
"CO-Prep™ offers laboratories increased capacity, automation of repetitive manual pipetting, increased accuracy, reduction in intra-sample contamination risk, and time for technicians to concentrate on other work.
The new CO-Prep™ instrument has received significant interest from customers in advance of the launch."
- Are you pleased with the level of customer interest progressing to sales, and is CO-Prep availability resulting in further instrument and PROmate sales please? Last update 7 months ago.

4 Question - What is the status of this project please? Last update 8 months ago.

18.08.2021 - Novacyt video to support virtual attendance at ASHG21

https://www.youtube.com/watch?app=desktop&v=6V-etfFdFJM :

Gemma Stokes: "Sequencing technology has advanced hugely in the last decade.
So one project we're looking into is speeding up nucleic acid detection from around an hour to about ten minutes.
The other project is so that we can detect more assays in one tube, which will give a lot more flexibility to our customers.
Of course our surveillance programme will continue, but we're also looking at ways of automating that completely so that we can focus on these other projects."
- It is not OK to make video's that include such statements with zero further shareholder update.

5 https://novacyt.com/wp-content/uploads/2021/06/Novacyt-2020-Full-Year-Results-Strategy-update-Final-website-version-for-29.06.2021-1.pdf - Strategy Update (pages 11-14).
Please state progress on these items and whether these items are even still valid, as we have a new CEO since this document was published.

6 Why is news being released solely on Twitter, and not via RNS.
Some news items can be expected to affect share price significantly, so RNS's in order.

Good spot Gazman -
What is a CEEC?
Central and Eastern European Countries, a generic term for a group of European countries, usually meaning former communist states in Europe.

11:06 Katie - "The status of the DHSC dispute, - what does this mean to you going forward exactly."

David - We continue to engage with the DHSC, we believe we have very strong grounds to assert our contractual rights.
However I think the important point as we seek resolution on the dispute by engaging with DHSC, we really want to build on our success with a real laser focus, so we are capitalising on our ability to focus on new opportunities in the private sector as we have demonstrated in the prior year.
We're also enhancing our international growth and reach and then as we have been so fortunate to develop a strong cash position, we will leverage that in the future not only in our organic investment in R&D in non-covid portfolio, but also enhancing our business development strategy.
I don't think it's all about the DHSC whilst we resolve that, I think we've really proven that we will continue to drive the business in parallel.

Katie: Let's touch upon your core capabilities. What would you say the core capabilities are and how do you intend to expand and leverage the key non-Covid 19 sales after the Pandemic?

David: I guess I said this at the start, it's the talent in the company and the quality of the team. So, whether it is the science, the innovation the R&D the manufacturing and supply team, our regulatory capability, through to our commercial capabilities.
That would be the first core capability that one can leverage.
The other thing is our extensive product portfolio not just in the clinical diagnostics arena but also in the research / life sciences arena from which we can drive innovation, and so we really have that strength of product design to manufacturing and our existing portfolio to build on.
Then we really want to, with our new commercial relations, build on that market led or customer led strategy going forwards to identify areas of unmet needs, that we can deploy our resources towards solutions for customers, where they have gaps now, in the context of infectious disease.
So what you will see are two things, one is the R&D team - with the commercial team - will pick which opportunities to go after in the future.
That’s in the organic piece of the investment going forward, and increasingly we are looking at enhancing our business development efforts to bolster the portfolio and really remain agile, the companies always been agile.

Katie: So what are your plans for further geographic expansion, are they particular markets you are focused on?

09:52 David: We started out very reliant on the UK, we still do a lot of business in the UK, but the clearest opportunity for us is to leverage our CE marked products across the European economic area, so a huge area for which we already have regulatory coverage.
Our additional regulatory hurdles [CTDA] we are going through in the UK to ensure our products are on the UK Market, but really across key markets in the European economic area is the most of this.
Then with targeted regulatory approvals in additional territories, and as we go forward and strengthen the company we will build on our business across key continents from America to Asia / Pacific.
We will with our 'first responder' strategy I mentioned earlier, we are strengthening our effort in regards to NGO's, Governments and Philanthropic organisations who support a number of developing countries.
So I think you might see it first things first across UK and then EEA and then really enhancing global reach step by step.

I've worked already in a preliminary sense on strategy with the team and we really see two core strands.
We are going to build the foundation of the business with clinical diagnostics with our instruments and our research use portfolio as an innovation engine for the future, but continue our second strand to be a global first responder towards major disease outbreak as we have done so for Covid-19.
And then lastly but not least, - I'm a Marketing guy by background, and the company has been a little more product lead in the past, - but I really want to be more market or customer lead serving our medical needs and picking important under-served issues in the future as we invest in the non-covid portfolio, so there will be more of an update on that in April with the full year results.

Katie: What’s next, - tell us more David

Yeah, really good question Katie, the first thing I would say, - sad to say Covid-19 is not going away, erm Yes from Pandemic to Epidemic or to Endemic, the disease will be here to stay and that varies by country.

We proudly innovated 15 new products last year, to tackle the evolving disease, we've developed a new customer base largely in the private sector, - film, media, employers etc , - help bring them to test their workforces.
We've contracted further with the department of health, and we've increased our NGO / Governmental / Philanthropic business as well abroad.
In that regard, and with the evolving variants of concern like Omicron we've remained relevant and remained on top of the pandemic innovating on the front line.

But to your point what is next, - we are now carefully considering opportunities for growth through to that situation beyond Covid-19, we are doing a number of assessments for where the key unmet needs are that we could best serve in infectious disease. The way I think about that really is that today if we are more 80/20 reliant on Covid [80% reliant on Covid products], from a business point of view we will evolve towards the opposite reliance.
In the future you will see the company innovate in other conditions in infectious disease.
As I say I will bring more colour to that evolution in the April time frame when we bring full year results, but we are excited that we really have the building blocks to do that.

For those who don't have this:
Preamble
David: What attracted me to the company is that the company had the key ingredients for future value creation.
I saw a solid number of building blocks, strong talents, a strong product portfolio, already established R&D and manufacturing supply chain, a commercial organisation with international reach, and accrued cash on balance in the bank, so essential building blocks which are hard to come by in any business.
I think I'm of the DNA to really make a difference in the company, take it to the next level and leave a legacy beyond that which the company has already achieved.

Last but not least, the other reason I joined was I felt comfortable at home with the team, a sense of belonging but a really talented team of individuals.

2.04 Katie:
Since joining in October last year, you have undertaken a strategic review of the business.
Tell us more about your key findings and the conclusions you made and how they support your view of the future direction of the business.

David: Yeah, so I have taken some time to really dig in and listen and learn about the company, and it's very clear to me that the companies great strength has been its ability to be agile and react quickly in the face of infectious disease previously reacting to outbreaks of Zika, Ebola, H1N1 swine flu, but actually Covid-19, - the first company in Europe to produce a CE mark in-vitro diagnostic test.
I guess the first thing is I really appreciated the strengths of the company and when one is thinking about strategy leveraging strength is the best start point.
It is of no surprise to any of us that in the infectious disease space that the risks are increasing.
We've seen that with the pandemic, with viruses, the ongoing problems with antimicrobial resistance. As we overuse antibiotics the understated problems we see with fungal infections, under appreciated or untreated and with climate change of course, diseases are moving with their ****that carry them around the world. So there is a whole list of reasons why infectious diseases are becoming even more problematic in a sense a resurgence perhaps of the past.
The way I have tried to think about the unmet needs the challenges and leveraging the strength of the company is to be much clearer for the company going forward with its vision, so we really want to hone that and become a leading global clinical diagnostic in the fight against infectious disease.
WE'VE done that before and we will do more in that regard.
With our purpose being to protect people by providing the right information at the right place at the right time, actionable health information, and protecting people from the invisible threat.

Evening Poidster -
This was a takeaway portion from the 25.01.2022 Proactive investor interview with DA.:

"..Then we really want to, with our new commercial relations, build on that market led or customer led strategy going forwards to identify areas of unmet needs, that we can deploy our resources towards solutions for customers, where they have gaps now, in the context of infectious disease.
So what you will see are two things, one is the R&D team - with the commercial team - will pick which opportunities to go after in the future.
That’s in the organic piece of the investment going forward, and increasingly we are looking at enhancing our business development efforts to bolster the portfolio and really remain agile, the companies always been agile."

I am expecting DA to say decisions have been made concerning infectious disease, - I'm not sure he will say exactly what areas we will be addressing, since he (and GM) has a history of not being explicit.
He sounds like he wants to be specific, - lets see what we get.

Here's my post from 12th April -
"NCYT shareholders are never going to experience true value, unless the company adopts less secretive ways of announcing deals with the likes of TATA MD and any other 'partnerships'.

From 25.01.2022 Strategy and Full Year 2021 Trading Update RNS

"In the interim, Novacyt continues to build a strong pipeline of business development opportunities for partnership, licensing, and M&A to strengthen the business and accelerate growth."

Also private testing labs.

IMO, officially, shareholders aren't aware of half of what has been going on, and until that knowledge is in the public domain, we will not realise full value."

++++

IMO nothing would work better for shareholder value creation than jointly developing a request for information for the 28th, and each individually sending THE SAME post to Mandy AND the INVESTOR MEET COMPANY platform.
That way we will know subsequently if our info request has been deliberately ignored.
Now that main members of BoD / some directors are on the same hymn sheet with respect to skin in the game, (and the unfathomable depth of the swamp the share price fall has dragged some shareholders into), we should list as many subjects that require answers as possible, then develop a simple information request consisting of a list.

I am aware the RNS states "The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform."
I'll take a guess that this presentation is what they want investor questions on.
As there are few opportunities each year for investors to query the board, we should be taking every opportunity to try to maximise shareholder value by requesting answers to questions the board would rather avoid.

I'll start the list with this issue:

1 What information can be provided on the deal between IT-IS International instruments and TATA MD in India?
Nothing is not an option.
++++
To encourage more participation by fellow posters, please add your query to the above, and we can send THE SAME TEXT when all have had an opportunity to post.

Not interested in 'the company can't tell us that - its probably confidential', let David decide that.
AFAIK the only subject that applies to is the DHSC dispute, everything else is fair game.

I am sick of the continued undervaluation of this share price, with no end in sight. I want us all to be owners of shares that are much closer to true value, so when we sell we sell nearer to full valuation.

Chas PB - Too easy for them to ignore.